Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Short-term Investments: 2019-2025

Historic Short-term Investments for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Pharming Group N.V's Short-term Investments rose 30.17% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 30.17%. This contributed to the annual value of $1.5 million for FY2024, which is 1.51% down from last year.
  • As of Q3 2025, Pharming Group N.V's Short-term Investments stood at $2.0 million, which was down 26.08% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Short-term Investments registered a high of $2.7 million during Q2 2025, and its lowest value of -$321,000 during Q1 2021.
  • Over the past 3 years, Pharming Group N.V's median Short-term Investments value was $1.5 million (recorded in 2024), while the average stood at $1.5 million.
  • As far as peak fluctuations go, Pharming Group N.V's Short-term Investments slumped by 450.00% in 2022, and later surged by 643.15% in 2023.
  • Pharming Group N.V's Short-term Investments (Quarterly) stood at $812,000 in 2021, then surged by 35.34% to $1.1 million in 2022, then surged by 39.04% to $1.5 million in 2023, then fell by 1.51% to $1.5 million in 2024, then spiked by 30.17% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.7 million for Q2 2025, and $1.6 million during Q1 2025.